Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Aaron Wallace

Orthopaedic Surgery Jonesboro, AR Medical Doctor

NPI 1275701963 CMS profile 883980

4802 E Johnson Ave, Jonesboro, AR 72401

Open in the dashboard

General payments

$4,859

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Aaron Wallace of Jonesboro, AR is reported in the CMS Open Payments database as having received $4,859 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 56th percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $595 28
2024 General $854 44
2023 General $680 37
2022 General $508 35
2021 General $1,529 32
2020 General $358 17
2019 General $334 19

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Aaron Wallace
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Aaron Wallace were reported at $595. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Aaron Wallace Orthopaedic Surgery median Middle half National median
2019 $334 $644 $140–$2,844 $163
2020 $358 $312 $75–$1,860 $114
2021 $1,529 $520 $117–$2,495 $132
2022 $508 $598 $128–$2,731 $149
2023 $680 $461 $128–$2,264 $160
2024 $854 $497 $134–$2,475 $164
2025 $595 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $3,157 140 payments
  2. Amgen Inc. $285 19 payments
  3. Djo, LLC $199 5 payments
  4. Orthalign Inc $163 2 payments
  5. Trice Medical, Inc. $151 1 payment
  6. DePuy Synthes Sales Inc. $86 4 payments
  7. Horizon Therapeutics plc $80 6 payments
  8. Vertex Pharmaceuticals Incorporated $67 3 payments
  9. Bioventus LLC $63 4 payments
  10. Conformis, Inc. $56 1 payment
  11. Other $551 27 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $4,097 209 payments
  2. Travel and Lodging $762 3 payments
Products named General payments · program years 2019–2025
  1. INSPACE $446 3 payments
  2. NANOTACK FLEX $403 1 payment
  3. MAKO $378 27 payments
  4. EVENITY $285 19 payments
  5. TRIATHLON $269 23 payments
  6. Prolia $269 18 payments
  7. COBRA $232 4 payments
  8. VARIAX $194 9 payments
  9. CINCHLOCK $173 2 payments
  10. SLINGSHOT $173 2 payments
  11. Other $2,970 140 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

828

Median for Orthopedic Surgery: 203

Drug cost

$10,230

Median for Orthopedic Surgery: $1,433

Branded share of claims

8.2%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Naloxone Hcl Generic 68 $4,301
Diclofenac Sodium Generic 120 $1,819
Celecoxib Generic 36 $882
Oxycodone Hcl Generic 138 $869
Meloxicam Generic 166 $647
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 68 $619
Promethazine Hcl Generic 118 $548
Mupirocin Generic 39 $316
Hydromorphone Hcl Generic 17 $84
Tramadol Hcl Generic 22 $57

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$148,526

Of which drugs: $35,017

Medicare patients

373

Average age 73

Services billed

7,563

229 women, 144 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 35%
Ischemic heart disease 33%
Depression 31%
Chronic kidney disease 23%
Heart failure 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg J3304 Office 42 2,336 $32,066
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 32 116 $557
Injection, methylprednisolone acetate, 1 mg J1010 Office 55 3,665 $364

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Zilretta
  • Pacira Pharmaceuticals Incorporated $11
$11 — 2,336
Exparel
  • Pacira Pharmaceuticals Incorporated $11
$11 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record